Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Tennessee Inlexzo Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield of TennesseePolicy N/A

    Gemcitabine (Inlexzo™) intravesical system

    Customize your policy alerts

    Sign up for all blue cross blue shield - tennessee policy alerts

    Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Inlexzo in adult members with high-risk, BCG-unresponsive nonmuscle invasive bladder cancer, subject to documented indication, treatment regimen, and continuation criteria.

    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyGemcitabine (Inlexzo™) intravesical system
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionSubmit documentation of no response to BCG and demonstrate that all coverage criteria are met to obtain prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 moInitial authorization period
    6 moInitial dosing phase
    18 moMaintenance dosing phase
    14 dosesTotal dose limit
    2Covered disease presentations

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial Therapy Criteria

    Covered when all of the following criteria are met.

    Initial therapy criteria

    • Disease presentation: The member has NMIBC with CIS or Ta/T1 papillary tumors without CIS.
    • Disease risk: The disease is high-risk.
    • BCG response: The disease is BCG-unresponsive.
    • Administration: The requested medication will be used as a single agent inserted intravesically.
    • Dosing schedule: The requested medication will be given once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months.Once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months

    Continuation Therapy Criteria

    Continuation coverage may be granted when all continuation criteria are met.

    Continuation therapy criteria

    • No persistent or recurrent disease: There is no evidence of persistent or recurrent NMIBC.
    • No progression: There is no evidence of disease progression.
    • Tolerability: There is no unacceptable toxicity while the member is receiving the current regimen.

    Indications outside the FDA-approved indication and the recognized compendial use are considered experimental/investigational and not medically necessary.

    Use for indications other than BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors, or nonmuscle invasive bladder cancer without carcinoma in situ, is considered experimental/investigational and not medically necessary.

    Prior Authorization and Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for gemcitabine (Inlexzo™) intravesical system. Authorization for up to 12 months may be granted for bladder cancer only when all coverage criteria are met and the required documentation is submitted.

    • NMIBC with carcinoma in situ (CIS) or Ta/T1 papillary tumors without CIS.
    • High-risk disease that is BCG-unresponsive.
    • Used as a single agent inserted intravesically.
    • Administered once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months.
    Documentation Required

    Document BCG Nonresponse

    Include chart notes or medical record documentation demonstrating no response to BCG when initiating the prior authorization review.

    Clinical Background

    Inlexzo (gemcitabine) is an intravesical system used to treat nonmuscle invasive bladder cancer. Its FDA-approved indication is for adults with BCG-unresponsive nonmuscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The policy also recognizes a compendial use for nonmuscle invasive bladder cancer without carcinoma in situ, subject to the applicable coverage criteria.

    Clinical Definitions

    BCG-unresponsive NMIBC with CIS
    TermBCG-unresponsive NMIBC with CIS
    Disease typeNonmuscle invasive bladder cancer with carcinoma in situ (CIS), with or without papillary tumors
    Treatment responseThe disease has not responded to Bacillus Calmette-Guérin (BCG) therapy
    NMIBC Disease Presentations
    TermNMIBC with CIS or Ta/T1 papillary tumors without CIS
    CIS presentationNonmuscle invasive bladder cancer with carcinoma in situ (CIS)
    Papillary tumor presentation

    Initial Treatment Authorization

    Initial Treatment

    Authorization of 12 months may be granted when all of the following criteria are met.

    Initial treatment criteria

    • Disease presentation: The member has NMIBC with CIS or Ta/T1 papillary tumors without CIS.
    • Disease risk: The disease is high-risk.
    • BCG response: The disease is BCG-unresponsive.
    • Administration: The requested medication will be used as a single agent inserted intravesically.

    Continued Treatment Authorization

    Continued Treatment

    Continuation authorization may be granted when all of the following are met.

    Continuation criteria

    • No persistent or recurrent disease: There is no evidence of persistent or recurrent NMIBC.
    • No progression: There is no evidence of disease progression.
    • Tolerability: There is no unacceptable toxicity while the member is receiving the current regimen.

    Dosing and Quantity Limits

    Inlexzo Dosing Schedule
    MedicationInlexzo (gemcitabine) intravesical system
    Initial dosingOnce every 3 weeks for up to 6 months
    Maintenance dosingOnce every 12 weeks for up to 18 months, following the initial dosing phase
    Continuation-Therapy Limit
    MedicationInlexzo (gemcitabine) intravesical system
    Continuation-therapy limitUp to a total of 14 doses
    Authorization periodAuthorization of 12 months may be granted for continued treatment
    Policy Summary
    PayerBlue Cross Blue Shield of Tennessee
    PolicyGemcitabine (Inlexzo™) intravesical system
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJanuary 30, 2027
    Next Review DateN/A
    Key ActionSubmit documentation of no response to BCG and demonstrate that all coverage criteria are met to obtain prior authorization.
    SourceLink
    On This Page
    Coverage CriteriaPrior Authorization and Provider ActionsClinical BackgroundClinical DefinitionsInitial Treatment AuthorizationContinued Treatment AuthorizationDosing and Quantity Limits
  1. Documentation of BCG nonresponse is necessary to initiate review.
  2. Denial Risk

    Unlisted Indications Not Covered

    Gemcitabine (Inlexzo™) is considered experimental/investigational and not medically necessary for indications other than non-muscle invasive bladder cancer without carcinoma in situ under the compendial use criteria.

    • Unlisted indications are not covered.
    Denial Risk

    Failure to Meet Coverage Criteria

    Coverage may be denied when the requested treatment does not satisfy the initial coverage criteria for bladder cancer.

    • The member does not have NMIBC with CIS or Ta/T1 papillary tumors without CIS.
    • The disease is not high-risk.
    • The disease is not BCG-unresponsive.
    • The medication is not requested as a single intravesical agent.
    • The requested dosing regimen does not follow once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months.
    Denial Risk

    Continuation Failure Criteria

    Reauthorization may be denied when continued treatment does not meet the continuation criteria. Up to 12 months of continued authorization, for a total of 14 doses, may be granted only when there is no evidence of persistent or recurrent NMIBC, disease progression, or unacceptable toxicity on the current regimen.

    • Persistent or recurrent NMIBC while on the current regimen.
    • Disease progression while on the current regimen.
    • Unacceptable toxicity while on the current regimen.
    Ta/T1 papillary tumors without carcinoma in situ (CIS)
  3. Dosing schedule: The requested medication will be given once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months.Once every 3 weeks for up to 6 months, followed by once every 12 weeks for up to 18 months